Loading company…
Zhuhai-based Rezubio is a targeted drug developer founded in 2019, working in oncology, immunology, and metabolic diseases.
Founded in 2019 and based in Zhuhai, China, Rezubio Pharmaceuticals Co., Ltd, trading as Rezubio, develops targeted drugs in oncology, immunology, and metabolic diseases. Founder and CEO Yusheng Xiong holds a Ph.D. in organic chemistry from the University of California and has more than 20 years of drug development experience at Merck Sharp & Dohme. In December 2025 the company raised over CNY 100 million in Series A funding led by new investor Lapam Capital, with Frees Fund and returning investor Riverhead Capital participating.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in